IRX4204 enters Phase II clinical trials in men with CRPC

According to a media release issued recently by the developers (Io Therapeutics), a first-in-class new investigational drug  called IRX4204 has just started Phase II clinical trials in men with “advanced” prostate cancer — by which the company seems to mean castration-resistant prostate cancer (CRPC).

At this time, there appears to be very little technical information available about IRX4204 — beyond what is available in the media release.

Neither this new trial nor any information about a prior Phase II trial in patients with a variety of different solid tumors appear to be listed on the web site.

The media release does not give a specific number to call or any other contact information that would help patients to discover eligibility information, so all that The “New” Prostate Cancer InfoLink can offer at this time is contact information for the Chairman and CEO of Io Therapeutics (Martin E. Sanders, MD), whose e-mail is and whose phone number (in Santa Ana, California) is (650) 219-5973.

One Response

  1. Minor Detail: Io Therapeutics is located in Santa Ana in Orange County, not in San Diego.

    “A Phase I/II study of IRX4204 conducted at the USC medical center demonstrated IRX4204 was well tolerated through escalation of multiple doses. In this clinical trial, indications of possible anti-tumor activity were observed across a broad range of cancers.”

    I note that there was also an earlier trial entitled “Oral NRX 194204 study in patients with advanced non-small cell lung cancer (NSCLC).” This trial was conducted by a company called NuRx Pharmaceuticals. No data appear to have been reported. I wonder whether Io Therapeutics is a “later version” of NuRx.

    “Retinoids and Rexinoids are small molecule drugs related to retinoic acid, which control expression of many types of genes through interaction with nuclear receptors. Two major nuclear receptor families for these molecules have been identified, so called RAR and RXR receptors. Within each family of receptors, there are three receptor subtypes, designated RARα, β, and γ, and RXRα, β, and γ. Discovery of these families of nuclear receptors has led to seminal advances in the understanding of cancer biology and the regulation of the immune system. For instance, rexinoid agonists have been demonstrated to induce apoptosis in many cancers. In addition, recent studies by Dr. Randy Noelle, one of the founders of Io Therapeutics, and others, have demonstrated that specific agonism of the RARα receptor plays a critical role in promoting the development of Treg lymphocytes, which suppress autoimmunity, while concurrently inhibiting the development of Th17 pro-inflammatory lymphocytes.”

    This info has been around since the early 1990s.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: